Publications:

Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.

Retrovirology

Oliveira, Maureen M; Ibanescu, Ruxandra-Ilinca RI; Anstett, Kaitlin K; Mésplède, Thibault T; Routy, Jean-Pierre JP; Robbins, Marjorie A MA; Brenner, Bluma G BG; ,

Publication Date: 2018-08-17

Variant appearance in text: CP: H51H

PubMed Link: 30119633

Variant Present in the following documents:

• 12977_2018_Article_440.pdf

View BVdb publication page

Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens.

Plos One

Smith, Robert A RA; Raugi, Dana N DN; Pan, Charlotte C; Coyne, Matthew M; Hernandez, Alexandra A; Church, Brad B; Parker, Kara K; Mullins, James I JI; Sow, Papa Salif PS; Gottlieb, Geoffrey S GS; ,

Publication Date: 2012

Variant appearance in text: CP: H51H

PubMed Link: 23028968

Variant Present in the following documents:

• Main text
• pone.0045372.pdf

View BVdb publication page